No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy

SU Tao; FANG Zhi-e; GUO Yu-ming; WANG Chun-yu; WANG Jia-bo; JI Dong; BAI Zhao-fang; YANG Li; XIAO Xiao-he

doi:10.1007/s11655-023-3560-0

Your Location：

Home >

Browse articles >

No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy

Original Article | Updated：2024-02-22

- No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy
- No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy
- 中国结合医学杂志（英文版） 2024年30卷第2期页码：99-106
- Affiliations：
  
  1.Renal Division, Department of Medicine, Peking University First Hospital, Beijing (100034), China
  2.Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing(400021), China
  3.Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing (100039), China
  4.China Military Institute of Chinese Materia, Fifth Medical Center of Chinese PLA General Hospital, Beijing (100039), China
  5.Phase Ⅰ Clinical Trials Unit, Department of Medicine for Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, Beijing (100039), China
  6.Department of Pharmacy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan (250000), China
  7.National Key Laboratory of Kidney Diseases, Beijing (100039), China
- Author bio：
  
  Prof. XIAO Xiao-he, E-mail: pharmacy_302@126.com
- Funds：
  
  National Key Technology R&D Program(2018ZX09101002-001-002);Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(ZYYCXTD-C-202005);the Science and Technology Project Affiliated to the Education Department of Chongqing Municipality(KJQN202215119)
- DOI：10.1007/s11655-023-3560-0
  中图分类号：
- 纸质出版日期：2024-02，
  
  网络出版日期：2023-11-09，
  
  录用日期：2023-07-17
Scan for full text
No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy[J]. 中国结合医学杂志（英文版）, 2024,30(2):99-106.

SU Tao, FANG Zhi-e, GUO Yu-ming, et al. No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy[J]. Chinese Journal of Integrative Medicine, 2024,30(2):99-106.
No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy[J]. 中国结合医学杂志（英文版）, 2024,30(2):99-106. DOI： 10.1007/s11655-023-3560-0.

SU Tao, FANG Zhi-e, GUO Yu-ming, et al. No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy[J]. Chinese Journal of Integrative Medicine, 2024,30(2):99-106. DOI： 10.1007/s11655-023-3560-0.

摘要

Abstract

Objective:

To assess the risk of aristolochic acid (AA)-associated cancer in patients with AA nephropathy (AAN).

Methods:

A retrospective study was conducted on patients diagnosed with AAN at Peking University First Hospital from January 1997 to December 2014. Long-term surveillance and follow-up data were analyzed to investigate the influence of different factors on the prevalence of cancer. The primary endpoint was the incidence of liver cancer

and the secondary endpoint was the incidence of urinary cancer during 1 year after taking AA-containing medication to 2014.

Results:

A total of 337 patients diagnosed with AAN were included in this study. From the initiation of taking AA to the termination of follow-up

39 patients were diagnosed with cancer. No cases of liver cancer were observed throughout the entire follow-up period

with urinary cancer being the predominant type (34/39

87.17%). Logistic regression analysis showed that age

follow-up period

and diabetes were potential risk factors

however

the dosage of the drug was not significantly associated with urinary cancer.

Conclusions:

No cases of liver cancer were observed at the end of follow-up. However

a high prevalence of urinary cancer was observed in AAN patients. Establishing a direct causality between AA and HCC is challenging.

关键词

Keywords

aristolochic acidhepatocellular carcinomaurinary cancerdrug safetyretrospective study

references

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing PDGFRB/YAP/CCN2 Axis Activity

Cidan Capsule in Combination with Adjuvant Transarterial Chemoembolization Reduces Recurrence Rate after Curative Resection of Hepatocellular Carcinoma:A Multicenter, Randomized Controlled Trial

Which Is Safer, Chinese Medicine or Western Medicine?Comparative Analysis Based on Chinese Spontaneous Reporting Database

Landscape of Hepatobiliary Adverse Drug Reactions Related to Preparations Containing Psoraleae Fructus and Its Application in Pharmacovigilance^*